Accumulation of ?-amyloid (A?) in the form of brain plaques is a hallmark of Alzheimer's disease (AD). Multiple studies in humans as well as mouse AD models have shown dystrophic neurites inside and surrounding A? plaques, and shown a slew of neuronal deficits correlated with A? deposition that likely contribute to memory loss and cognitive decline seen in AD. A? accumulation could be the result of excessive production or defective clearance of A?, or a combination of both. Many studies have focused on the production of pathogenic forms of A?, in particular A?42. Much less is known about the clearance process of A? from the brain. A strong indication that defective A? clearance is involved in the pathogenesis of AD comes from studies showing that the concentration of A?42 in the cerebrospinal fluid (CSF) is lower in AD patients relative to controls very early in the disease process. In preliminary studies, we have observed a rapid and efficient uptake of dextran rhodamine and A?42 by meningeal macrophages. By specifically ablating meningeal macrophages in the brain, we will test the hypothesis that meningeal macrophages are important in the clearance of A? and therefore their absence contributes to an incrased AD plaque size. We further hypothesize that meningeal macrophages do not work as effectively in AD as in healthy undividuals, as measured by number and/or phagocytic capacity and/or activation state. The proposed studies will elucidate important functions of meningeal macrophages in regulating amyloid clearance and deposition in the pathogenesis of AD.

Public Health Relevance

The brain has a variety of mechanisms to effect the clearance of catabolites and toxic molecules, such as the ones that cause the formation of plaques in Alzheimer?s disease. We will focus on a type of brain macrophage present in the meninges. These meningeal macrophages are normally adept at taking up toxic compounds and catabolites; we postulate that ablation of this clearance system could lead to accelerated onset of Alzheimer?s disease, or a more severe disease with larger amyloid plaques.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AG059220-02
Application #
9722153
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Opanashuk, Lisa A
Project Start
2018-06-15
Project End
2020-02-28
Budget Start
2019-03-01
Budget End
2020-02-28
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016